Most people never see what colon cancer actually looks like. A gastroenterologist breaks it down, showing how tiny polyps silently grow into dangerous tumours.

Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped ​reduce abnormal growths in the colon in patients with a rare ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Accurate information about Lynch syndrome is essential. As more people discuss hereditary cancer online, misinformation ...

Men face higher chronic disease rates after 40. Learn which medical tests doctors say are vital for preventing heart attacks, ...

Further funding has been secured for a cancer trial study, which is developing a new test to detect colorectal cancer and ...

Hakka Fujian Tulou villages blend ancient architecture, nature-based wisdom, and living heritage, thriving through culture and tourism.Beijing, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- China's ...

A recent study reveals that integrating Artificial Intelligence (AI) into colon cancer diagnosis over the past five years has ...

Kymera shows strong KT-621 Phase 1b efficacy, solid safety, platform validation, cash runway and growth potential in key ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a ...

The Faculty of Medicine, Chulalongkorn University, in collaboration with the Faculty of Engineering, has developed “Deep GI,” ...